HealthCare Global Enterprises posts Q1 FY25 PAT higher at Rs. 12.1 Cr

Our centers are performing as expected or even better

Biocon posts Q1 FY25 PAT higher at Rs. 660 Cr

This strong performance was primarily on account of a one-time gain from the strategic collaboration between Biocon Biologics and Eris Lifesciences.

Gland Pharma posts 16% revenue growth in Q1 FY25

The drugmaker's net profit slipped 26 per cent on-year to Rs 143.8 crore

Eris Lifesciences posts Q1 FY25 at Rs. 89 Cr

EBITDA at Rs. 250 crore, up 47% YoY, with 35% EBITDA margin

Dabur Q1 FY25 consolidated net profit up 8% at Rs 500 Cr

Q1 Consolidated operating profit Up 8.3%; revenue grows 7% to Rs 3,349 crore

Aarti Drugs posts Q1 FY25 PAT lower at Rs. 33.3 Cr

Steps taken by India for preparedness against future pandemics

Integrated Disease Surveillance Programme (IDSP) strengthened to improve disease surveillance and rapid data reporting

Mankind Pharma to acquire 100% stake in Bharat Serums from Advent for Rs. 13,630 Cr

Acquisition in line with Mankind’s stated objective to expand its presence in high entry barrier complex portfolios and high potential OTX brands

Cupid widens e-Commerce presence on leading Indian platforms

This strategic move aims to make Cupid's high-quality products more accessible to consumers nationwide

Piramal Pharma Q1 FY25 net loss narrows

EBITDA grew by 31% YoY with EBITDA margin of 11%, a YoY improvement of over 170bps vs. Q1FY24